Skip to content

Author

V. Katanaev

We have 4 of 200 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Comprehensive phytochemical study of Galianthe thalictroides: isolation of three new compounds, structural revision of β-carbolines, and evaluation of cytotoxic and anti-wnt activities

The discovery of novel bioactive compounds, together with evidence of pathway-specific effects, highlights the plant’s potential as a source of structurally diverse and pharmacologically relevant metabolites for anticancer research.

Patrícia de Oliveira Figueiredo, O. Kirchhoffer, L. Marcourt et al. · 0 citations
#gene editing Review Sep 2026

Novel and Emerging Therapies for Childhood-Onset Movement Disorders.

This work surveyed the literature, major conference proceedings, and expert networks to identify therapies approved, in clinical development, or supported by compelling preclinical data between 2022 and 2025, and focused on small molecules and genetic therapies for conditions in which movement disorders represent a pro...

C. D. de Gusmao, V. Katanaev, Laura Silveira-Moriyama et al. · 1 citation
Open access Jul 2026

Gene supplementation therapy restores motor deficits in Gnao1[C215Y] mice and proves broad efficacy in C. elegans model.

It is demonstrated that overexpression of the wild-type protein mitigates behavioral abnormalities and restores functional neuronal deficits in young adult mice, thereby supporting the development of AAV-mediated gene augmentation strategies to counteract the effects of GNAO1 variants in patients.

Germana Cocozza, T. D’Andrea, M. Di Rocco et al. · 0 citations
Aug 2026

MYC-driven BYSL overexpression promotes hepatocellular carcinoma by suppressing nucleolar stress and inactivating the RPL5/RPL11-MDM2-p53 pathway.

It is revealed that BYSL acts as a pivotal downstream mediator of MYC-regulated ribosome biogenesis and promotes hepatocellular carcinoma progression, suggesting that BYSL may represent a potential therapeutic target for hepatocellular carcinoma.

Heyuan Zhao, Hui-Ying Liu, Xia Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.